Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exa-cel in severe sickle cell disease (HbSC genotype)
NCT05951205Phase 3Withdrawn
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2027
- Primary completion
- Dec 2033
- Modality
- Gene Silencing, CRISPR-Cas9, Cell Therapies
01
Overview
A Phase 3 trial of exagamglogene autotemcel in sickle cell disease (SCD), sponsored by Vertex Pharmaceuticals. Planned start Jul 2027; status: withdrawn.
02
Drugs
exagamglogene autotemcel
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05951205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05951205.